J BUON [JOURNAL]
Sun
200 papers
Efficacy of paclitaxel and S-1 combined with apatinib in the conversion therapy for unresectable advanced gastric cancer.
Wu Z, Fang H
J BUON · 2021 · PMID 34565008
PURPOSE: To explore the safety and effectiveness of paclitaxel and tegafur, gimeracil and oteracil potassium (S-1) combined with apatinib in the conversion therapy for unresectable advanced gastric cancer. METHODS: A tot...
PURPOSE: To explore the safety and effectiveness of paclitaxel and tegafur, gimeracil and oteracil potassium (S-1) combined with apatinib in the conversion therapy for unresectable advanced gastric cancer. METHODS: A total of 66 patients with advanced gastric cancer received treatment with paclitaxel + S-1 + apatinib. Patients evaluated as resectable advanced gastric cancer by the multiple disciplinary team (MDT) underwent the surgery. The clinical efficacy and adverse reactions of the patients receiving conversion therapy and the related indicators of those undergoing operation were recorded. Later, the survival of the patients was compared between successful conversion therapy (surgery) group and unsuccessful conversion therapy (non-surgery) group. RESULTS: All the 66 patients completed 3-7 cycles of chemotherapy, with a median of 5 cycles, and the objective response rate (ORR) after conversion therapy was 71.2% (47/66). Among them, 48 patients received operation for (225.2±37.3) min on average, with the intraoperative blood loss of (168.2±40.9) mL and (50.9±12.3) intraoperative dissected lymph nodes, including 34 (70.8%) cases of R0 resection. According to the postoperative pathological tumor regression grading (TRG), there were 2 (4.2%) TRG 0 cases, 10 (20.8%) TRG 1 cases, 28 (58.3%) TRG 2 cases and 8 (16.7%) TRG 3 cases. The follow-up results revealed that the one-year overall survival (OS) of the patients was 93.8% (45/48) in successful conversion therapy (surgery) group and 61.1% (11/18) in unsuccessful conversion therapy (non-surgery) group. CONCLUSION: Paclitaxel and S-1 combined with apatinib can achieve a higher R0 resection rate, and improve the survival rate of patients with successful conversion therapy, showing high safety and efficacy.
Effects of MSCT enhanced scan image diagnosis on clinical outcome of patients after radical gastrectomy and its influence on misdiagnosis rate.
Yang D, Zhou Y, Peng Z … +1 more , Ou N
J BUON · 2021 · PMID 34565007
PURPOSE: To explore the effect of multi-slice spiral computed tomography (MSCT) enhanced scan image diagnosis on clinical outcome of patients after radical gastrectomy and its influence on misdiagnosis rate. METHODS: A t...
PURPOSE: To explore the effect of multi-slice spiral computed tomography (MSCT) enhanced scan image diagnosis on clinical outcome of patients after radical gastrectomy and its influence on misdiagnosis rate. METHODS: A total of 62 patients diagnosed with gastric cancer and undergoing radical gastrectomy were selected. All patients were reexamined 2-6 months after operation. Conventional CT and MSCT enhanced scan were performed for image diagnosis, and the results were compared with those of gastroscopic biopsy. Finally, the misdiagnosis rate, negative predictive value, positive predictive value, sensitivity and specificity of conventional CT and MSCT enhanced scan for postoperative recurrence were analyzed. RESULTS: According to the results of gastroscopic biopsy, there were 35 cases suspected of recurrence, and 27 cases without postoperative recurrence. The specificity and sensitivity of conventional CT and MSCT enhanced scan were 85.19% vs. 92.59%, and 65.71% vs. 92.16%, respectively. Both specificity and sensitivity of MSCT enhanced scan were higher than those of conventional CT, with statistically significant differences (p<0.05). MSCT enhanced scan had a lower misdiagnosis rate for postoperative recurrence than conventional CT (5.71% vs. 22.86%) (p<0.05). Moreover, the negative predictive value and positive predictive value of conventional CT and MSCT enhanced scan were 65.71% vs. 86.21%, and 85.19% vs. 93.94%, respectively. The results showed that MSCT enhanced scan had higher negative predictive value and positive predictive value for postoperative recurrence than conventional CT, with statistically significant differences (p<0.05). CONCLUSION: MSCT enhanced scan image diagnosis is of great significance for assessing the condition of disease, determining the recurrent foci after radical gastrectomy, and developing the subsequent therapeutic regimen.
Clinical and pathological significance of proliferation index and p53 expression in gastric adenocarcinoma.
Zindovic M, Vuletic M, Milenkovic S … +4 more , Jancic S, Krstic M, Zindovic D, Milosevic V
J BUON · 2021 · PMID 34565006
PURPOSE: The purpose of our work was to investigate the association between proliferative index [proIDX] and expression index p53 (p53IDX) with the clinical and pathological characteristics of gastric adenocarcinoma. MET...
PURPOSE: The purpose of our work was to investigate the association between proliferative index [proIDX] and expression index p53 (p53IDX) with the clinical and pathological characteristics of gastric adenocarcinoma. METHODS: The biopsy material of 90 patients operated on for gastric cancer was routinely processed in paraffin and archived. After the histopathological report was made, two study groups were formed, the first group (n=45) comprised biopsies with intestinal carcinoma and the second (n=45) biopsies of diffuse gastric cancer. In both cases, the control group consisted of biopsies of surrounding non-tumor tissue The routine Hematoxylin-Eosin and immunohistochemical ABC method with anti-Ki67 and anti-p53 antibodies was applied at sections 3-5 μm thick. The expression of Ki67 and p53 was quantified stereometrically. For statistical analysis SPSS (19.0) was used. RESULTS: Significantly higher Ki67 expression was found in both types of adenocarcinoma compared to the control group, as well as significant association of proIDX with most of testing parameters. Expression of p53 was significantly higher in the intestinal type compared to the diffuse type and the control group and was significantly associated with age and histological grade. Diffuse type particulary showed, significant association of p53IDX with most of the histological parameters tested. CONCLUSION: Our results point a highly significant correlation of the Ki67 and p53 expression with indicators of gastric adenocarcinoma progression, which may help to identify patients with an aggressive gastric adenocarcinoma phenotype.
Influences of lncRNA HEIH and DKK3 on the clinical features and prognosis of gastric cancer.
Dong H, Li F, Jin A
J BUON · 2021 · PMID 34565005
PURPOSE: To detect differential expressions of HEIH and DKK3 in gastric cancer (GC) samples, and to elucidate their influences on clinical features and disease prognosis. METHODS: The expression levels of HEIH and DKK3 i...
PURPOSE: To detect differential expressions of HEIH and DKK3 in gastric cancer (GC) samples, and to elucidate their influences on clinical features and disease prognosis. METHODS: The expression levels of HEIH and DKK3 in GC tissues and adjacent normal ones (>5 cm) were detected by qRT-PCR. Correlation between HEIH and DKK3 levels in GC tissues was analyzed by Pearson's correlation analysis. Sensitivity and specificity of detecting HEIH and DKK3 levels in diagnosing GC were assessed by reactive oxygen species (ROC). 5-year survival in each patient was followed up. Risk factors of prognosis in GC patients were examined by Cox regression model. RESULTS: HEIH was upregulated, and DKK3 was downregulated in GC tissues, displaying a negative correlation. Both HEIH and DKK3 were correlated to tumor diameter, lymph node metastasis and TNM staging. Combined detection of HEIH and DKK3 levels showed high specificity and sensitivity in the diagnosis of GC. Tumor diameter, lymph node metastasis, TNM staging, HEIH and DKK3 levels were independent risk factors for the prognosis of GC. CONCLUSION: The upregulated HEIH and downregulated DKK3 in GC samples showed a negative correlation between each other. HEIH and DKK3 levels were closely linked to tumor diameter, lymph node metastasis and TNM staging in GC patients. These are promising biomarkers for predicting the prognosis of GC.
Short- and medium-term outcomes after uniportal and multiportal video-assisted thoracic surgery lobectomy in elderly patients with non-small cell lung cancer.
Zhong D, Lin Q, Zhang J … +2 more , Liu Y, Zhan Z
J BUON · 2021 · PMID 34565004
PURPOSE: To investigate the short- and medium-term outcomes following treatment with uniportal video-assisted thoracic surgery lobectomy (uniportal VATS) in elderly patients with non-small cell lung cancer (NSCLC). METHO...
PURPOSE: To investigate the short- and medium-term outcomes following treatment with uniportal video-assisted thoracic surgery lobectomy (uniportal VATS) in elderly patients with non-small cell lung cancer (NSCLC). METHODS: We conducted a retrospective analysis on the clinical and follow-up data of 74 elderly patients with NSCLC who underwent uniportal VATS between January 2015 and January 2020. One-to-one propensity score matching (PSM) was employed to select 71 elderly patients with NSCLC who underwent multiportal video-assisted thoracoscopic lobectomy (multiportal VATS) during the same period. RESULTS: The baseline characteristics of the two patient groups were comparable, with no statistically significant differences in postoperative complications, operation time, conversion to thoracotomy, or lymph node dissection. The amount of intraoperative blood loss and postoperative pain were lower in the uniportal VATS group than in the multiportal VATS group. The 3-year overall survival and disease-free survival of the two groups were similar. CONCLUSIONS: Uniportal VATS achieved similar short- and medium-term outcomes as Multiportal VATS in elderly patients with NSCLC.
Upfront thoracic radiotherapy to primary lesion improves outcomes in patients with stage IV non-small cell lung cancer harboring EGFR mutations.
Kotek Sedef A, Akkus Yildirim B, Topkan E … +1 more , Taner Sumbul A
J BUON · 2021 · PMID 34565003
PURPOSE: The role of thoracic radiotherapy in the treatment of metastatic EGFR mutant non-small cell lung cancer (NSCLC) patients in literature data are insufficient.The purpose of this study was to examine the effective...
PURPOSE: The role of thoracic radiotherapy in the treatment of metastatic EGFR mutant non-small cell lung cancer (NSCLC) patients in literature data are insufficient.The purpose of this study was to examine the effectiveness of upfront thoracic radiotherapy in metastatic EGFR mutant NSCLC patients treated with chemotherapy or tyrosine kinase inhibitors (TKI). METHODS: This study was designed as a hospital-based retrospective observational case-series study. A total of 141 patients with metastatic EGFR mutant NSCLC who were followed in two different oncology centers in Turkey between 2014 and 2019 have been included into this study. RESULTS: The median patient age was 63 years (range 35-91). EGFR mutation results of exon 19 deletion, exon 21 mutation and exon 18 mutation were found in 82 (58.2%), 56 (39.7%) and 3 (2.1%) patients, respectively.The median follow-up time was 22 months and 94 (33.3%) patients died during follow-up. Median overall survival (OS) was 26 months and progression free survival (PFS) (for first line treatment) was 10 months for the whole cohort, respectively. Radiotherapy was given to the primary tumor site in 32 (22.6%) patients. Patients receiving radiotherapy to primary tumor site had better OS than those who had not (31 versus 23 months respectively, p=0.02). Survival advantage was also seen for patients group taking TKI at upfront setting (33 versus 23 months respectively, p=0.05). CONCLUSION: In this study, we have shown that upfront thoracic radiotherapy to primary lesion as combination with EGFR-TKI treatment may improve the outcome in advanced stage IV NSCLC patients harboring EGFR mutations.
Clinical significance of detecting HDL and miR-103 levels in lung carcinoma patients.
Zhang Y, Zhang X, Han Z
J BUON · 2021 · PMID 34565002
PURPOSE: To elucidate the clinical significance of microRNA (miR)-103 and HDL in influencing pathological features in lung carcinoma, and to predict chemotherapy efficacy of lung carcinoma according to the expression cha...
PURPOSE: To elucidate the clinical significance of microRNA (miR)-103 and HDL in influencing pathological features in lung carcinoma, and to predict chemotherapy efficacy of lung carcinoma according to the expression changes of miR-103 and HDL before and after chemotherapy. METHODS: Serum levels of miR-103 and HDL were detected in lung carcinoma patients (n=60) and healthy subjects (n=60) by qRT-PCR. The correlation between miR-103 and HDL in serum samples of lung carcinoma patients was assessed. In addition, their influence on pathological features in lung carcinoma were analyzed. Changes in HDL and miR-103 levels in lung carcinoma patients based on their therapeutic efficacy were evaluated and analyzed. RESULTS: Serum levels of miR-103 and HDL were lower in lung carcinoma patients than those of healthy subjects. MiR-103 level was correlated to that of HDL in serum samples of lung carcinoma patients. HDL level was correlated to smoking, TNM staging and presence of lymph node metastasis of lung carcinoma, while miR-103 level was correlated to TNM staging and presence of lymph node metastasis of lung carcinoma. Serum levels of miR-103 and HDL were significantly enhanced in lung carcinoma patients achieving PR after chemotherapy (p<0.05). No significant differences in miR-103 and HDL levels before and after chemotherapy were observed in lung carcinoma patients achieving stable disease (SD) or progressive disease (PD). CONCLUSION: MiR-103 and HDL are involved in the progression of lung carcinoma. Their expression changes after chemotherapy can be utilized for predicting therapeutic efficacy and prognosis in lung carcinoma patients.
Application effect of dexmedetomidine combined with flurbiprofen axetil and flurbiprofen axetil monotherapy in radical operation of lung cancer and evaluation of the immune function.
Zong S, Du J, Chen Y … +1 more , Tao H
J BUON · 2021 · PMID 34565001
PURPOSE: To explore the effect of dexmedetomidine combined with flurbiprofen axetil on postoperative analgesia and immune function in patients with lung cancer after radical operation. METHODS: 60 lung cancer patients un...
PURPOSE: To explore the effect of dexmedetomidine combined with flurbiprofen axetil on postoperative analgesia and immune function in patients with lung cancer after radical operation. METHODS: 60 lung cancer patients undergoing open chest radical surgery were selected and randomly divided into D & F Group (dexmedetomidine combined with flurbiprofen axetil) and F Group (flurbiprofen axetil), with 30 cases in each group. Before induction of general anesthesia, Group F was administered intravenous flurbiprofen axetil, and in D & F group, dexmedetomidine and erfuorbiprofen axetil were injected. RESULTS: At T2 (intubation) and T3 (extubation), map and HR in D & F group were significantly lower than those in F group (p<0.05). The extubation quality score of D & F group was significantly lower than that of F group (p<0.05). At 6 h and 12 h after operation, visual analogue scale (VAS) score and Bruggrmann comfort scale (BCS) score of D & F group were significantly lower than that of F group (p<0.05). The dosage of sufentanil and the times of pressing analgesia pump in group D & F were significantly less than those in group F (p<0.05). NK cells, CD3 + T cells and CD4 + / CD8 + in the D & F group were significantly higher than those in F group at 12h, 24h, 48 h and 1 week after operation (p<0.05). CONCLUSIONS: Flurbiprofen axetil can improve postoperative pain, but combined with dexmedetomidine better effect, postoperative comfort and immune function of patients were significantly improved.
Let-7a targets Rsf-1 to modulate radiotherapy response of non-small cell lung cancer cells through Ras-MAPK pathway.
Shi Z, Liu J, Sun D
J BUON · 2021 · PMID 34565000
PURPOSE: Radiotherapy is the most commonly selective medical treatment for non-small cell lung cancer (NSCLC) and the multiple underlying mechanisms are considered as the effectively theoretical foundation. Herein, we in...
PURPOSE: Radiotherapy is the most commonly selective medical treatment for non-small cell lung cancer (NSCLC) and the multiple underlying mechanisms are considered as the effectively theoretical foundation. Herein, we investigated the effects of let-7a targets Rsf-1 on modulating the radiotherapy response in NSCLC cells by Ras-MAPK pathway. METHODS: A549 cells were divided into different groups to investigate the role of let-7a and Rsf-1 on the radiotherapy response. The expression of let-7a and Rsf-1 were detected by RT-PCR. Bioinformatic analysis indicated that Rsf-1 is the target of let-7a. The binding site of let-7a in the Rsf-1 3'UTR was detected based on double luciferase reporter assay and Western blot. The cell variability and proliferation were assessed by MTT and colony formation assay. The expression levels of Ras-MARK signaling pathway related proteins were assessed by RT-PCR. RESULTS: RT-PCR results showed that radiotherapy could up-regulate the expression of let-7a, thereby reducing the expression of Rsf-1, and the correlation between the two factors was negatively correlated. At the same time, let-7a overexpression and Rsf-1 silencing could further reduce the activity of A549 cells after radiotherapy, have an inhibitory effect on cell proliferation and inhibit the expression of related proteins in the Ras-MAPK pathway. CONCLUSIONS: Rsf-1 is the target of Let-7a. The present study provides evidence that let-7a targeting Rsf-1 can modulate radiotherapy response in NSCLC cells through Ras-MAPK pathway.
Analysis of risk factors related to breast cancer metastasis: a retrospective nested case-control study.
Liu Y, Liu B, He Y … +6 more , Li Z, Li X, Wang D, Wang Z, Xu Y, Yu Q
J BUON · 2021 · PMID 34564999
PURPOSE: To explore the laboratory indexes related to breast cancer metastasis, so as to provide scientific basis for the control of breast metastasis. METHODS: A retrospective cohort-based nested case-control study was...
PURPOSE: To explore the laboratory indexes related to breast cancer metastasis, so as to provide scientific basis for the control of breast metastasis. METHODS: A retrospective cohort-based nested case-control study was used to screen 732 breast cancer patients recorded in the First and the Third Hospitals of Jilin University's electronic medical record system between January 2008 through December 2015 without metastasis at admission. Those with subsequent metastasis were classified as the metastasis group and those without metastasis as the control group. The suspected confounders were matched by propensity score matching, then univariate analysis was conducted, and the variables with statistical significance were included in multivariate conditional logistic regression analysis. RESULTS: A total of 86 patients were matched in the transfer group and 315 in the control group, with a total sample size of 401.In univariate analysis, fasting plasma glucose (FPG), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP) and direct bilirubin (DBIL) in two groups were statistically different (p<0.05), multiple conditional logistic regression showed that FPG (OR=1.335) and ALP (OR=1.016) were factors related to breast cancer metastasis. CONCLUSIONS: For breast cancer patients, the higher FPG and ALP levels may be associated with metastasis. Therefore, daily monitoring and control of these indicators may be helpful for the control of cancer metastasis.
The new normal for breast cancer surgery during COVID-19 pandemic: An international survey conducted by SENATURK.
Canturk NZ, Guler SA, Kocdor MA … +1 more , Simsek T
J BUON · 2021 · PMID 34564998
PURPOSE: The COVID-19 pandemic has changed the way many health institutions approach their workload. Physicians managing patients with cancer now have to deal not only with the disease but also the restrictions and limit...
PURPOSE: The COVID-19 pandemic has changed the way many health institutions approach their workload. Physicians managing patients with cancer now have to deal not only with the disease but also the restrictions and limitations imposed because of the global pandemic. We aimed to determine how surgical preferences in breast cancer management were affected globally using a questionnaire-based survey. METHODS: Under the auspices of the Turkish Senology Society (SENATURK) we asked 122 surgeons from 27 countries to reply to a 26-question survey designed to measure the impact of COVID-19 on their surgical practice when treating patients with breast cancer. RESULTS: The characteristics of participant surgeons were statistically similar when comparing the participants' answers from Turkey and other countries. From the responses given to our questionnaire, it was understood that breast cancer surgery decreased by 25% (p<0.05) in institutions all over the world, including Turkey, but there was no change in the approach technique to the axilla. CONCLUSIONS: Globally breast surgeons have adapted to the new normal due to the COVID-19 pandemic. Many surgical approaches and some follow up protocols have been changed, although the degree of change has varied from country to country. In addition, the availability of multidisciplinary case conferences has been reduced in some centers which may affect the quality of services provided to patients.
Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data.
Ates O, Oksuzoglu OB, Aktas BY … +8 more , Karadag I, Esen S, Karakaya S, Uncu D, Erol C, Gurbuz M, Yalcin B, Aksoy S
J BUON · 2021 · PMID 34564997
PURPOSE: Recently, neoadjuvant treatment approach has gained importance in locally advanced HER-2 positive breast cancer. Adding pertuzumab increases pathological complete response (pCR). In this study, we aimed to exami...
PURPOSE: Recently, neoadjuvant treatment approach has gained importance in locally advanced HER-2 positive breast cancer. Adding pertuzumab increases pathological complete response (pCR). In this study, we aimed to examine the clinicopathologic features that predict the pCR in patients receiving neoadjuvant pertuzumab, trastuzumab, and chemotherapy in locally advanced HER2 positive breast cancer. METHODS: Locally advanced HER2 positive breast cancer patients who were followed up in 4 different oncology centers and received 4 cycles of pertuzumab, trastuzumab and taxane were retrospectively evaluated. A total of 58 (92%) patients received anthracycline chemotherapy before combination of dual her-2 blockade and taxanes. Fisher's and chi-square tests were used for nominal variables and numeric data analyses. RESULTS: A total of 63 female patients were included in the study. Their median age was 46 years (21-75) and 40 (63.5%) patients were premenopausal. Median tumor size was 25 mm (2-70) and there were 22 (34.9%) patients with Stage 3a. pCR was 66% and 75% in the whole group and in the hormone negative group, respectively. Statistically significant increase was found in pCR in patients with grade 3 tumors and cerbB2 with 3+ immunohistochemical staining. No relationship was found between pCR and age at diagnosis, menopausal status, tumor infiltrating lymphocyte, dose-dense anthracycline, Ki67≥40, body mass index (BMI) ≥ 30 kg/m2 and accompanying DCIS. CONCLUSION: Four cycles of pertuzumab, trastuzumab and taxane after neoadjuvant anthracycline for locally advanced HER2 breast cancer are associated with increased pCR in patients with grade 3 tumors and high cerbB2 expression.
Nomograms predicting overall survival and cancer-specific survival in metaplastic breast cancer patients.
Shi H, Yu L, Mai J … +2 more , Zhang P, Fang K
J BUON · 2021 · PMID 34564996
PURPOSE: To establish and validate nomograms to predict the overall survival (OS) and cancer-specific survival (CSS) of metaplastic breast cancer(MBC) patients. METHODS: We retrospectively enrolled 948 patients with MBC...
PURPOSE: To establish and validate nomograms to predict the overall survival (OS) and cancer-specific survival (CSS) of metaplastic breast cancer(MBC) patients. METHODS: We retrospectively enrolled 948 patients with MBC from the Surveillance, Epidemiology and End Results (SEER) database between 2010 and 2016.Univariate and multivariate Cox analyses were used to determine independent prognostic factors to be included in nomograms for predicting the probabilities of OS and CSS at 1, 2, and 3 years. The concordance index (C-index), receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis were used to check the effectiveness and clinical application of the models. RESULTS: In total, 948 patients were enrolled and randomly assigned to the training (n=664) and validation (n=284) cohorts. Age, tumor size, ethnicity, AJCC stage, radiotherapy, and surgery were identified as independent prognostic factors for OS, while age, tumor size, and AJCC stage were identified as independent prognostic factors for CSS (all p <0.05) and further incorporated into the nomograms. The C-indices for OS and CSS predictions were 0.790 and 0.792 for internal validation and 0.772 and 0.768 for external validation. Both the internal and external validation calibration plots showed excellent agreement between the nomogram predictions and actual survival. ROC curves demonstrated good discriminative ability of the nomograms. CONCLUSION: Nomograms were developed to predict OS and CSS in patients with MBC. These nomograms can help clinicians make more accurate survival assessments and identify patients at high risk of death.
The reliability of breast cancer surgery in a regional pandemic hospital during the COVID-19 pandemic: Delay or Do?
Turan U, Kaan Sanal A, Irkorucu O
J BUON · 2021 · PMID 34564995
PURPOSE: The purpose of this study was to examine the effect of COVID-19 infection on the morbidity and mortality rates of breast cancer patients performed in the East Mediterranean region of Turkey during the COVID-19 p...
PURPOSE: The purpose of this study was to examine the effect of COVID-19 infection on the morbidity and mortality rates of breast cancer patients performed in the East Mediterranean region of Turkey during the COVID-19 pandemic and to share the results of those investigations. METHODS: This retrospective study included all breast cancer patients that underwent surgery during the COVID-19 pandemic in the General Surgery Clinic of Adana City Training and Research Hospital, a regional pandemic hospital, between March 11, 2020 and December 25, 2020. The patients were evaluated preoperatively and postoperatively (the first 30 days) in terms of COVID-19 infection. Moreover, these patients were also evaluated in terms of admission to the hospital, length of hospital stay, and mortality due to COVID-19 infection during the follow-up period of the study. RESULTS: Included in the study were 139 patients that underwent surgery for breast cancer during the pandemic period, with no observed mortality or morbidity associated with COVID-19 in any patient postoperatively within the first 30 days. In addition, within 121.22±70.05 days, the mean and standard deviation of the study's follow-up period, 19 patients (15.7%) were admitted to the hospital with a suspected COVID-19 infection (after the first 30 days postoperatively) and 6 of them (4.3%) returned a positive PCR test. All of the COVID-19 positive patients (6 patients, 4.3%) were hospitalised and 3 of them (2.2%) died due to the COVID-19 infection. CONCLUSION: Breast cancer surgery can be performed safely during the COVID-19 pandemic period after taking the necessary precautions.
Three-dimensional DSA guidance reduces complications and enhances the safety during interventional treatment for patients with hepatocellular carcinoma.
Li R, Zhang F
J BUON · 2021 · PMID 34564994
PURPOSE: The objective of this study was to investigate the therapeutic effect and safety of three-dimensional digital subtraction angiography (3D-DSA) in interventional therapy for hepatocellular carcinoma (HCC) patient...
PURPOSE: The objective of this study was to investigate the therapeutic effect and safety of three-dimensional digital subtraction angiography (3D-DSA) in interventional therapy for hepatocellular carcinoma (HCC) patients. METHODS: A total of 62 HCC patients who underwent interventional therapy were selected and divided into control group (n=31, receiving ordinary two-dimensional DSA) and observation group (n=31, undergoing 3D-DSA). The dosage of contrast agent, operation time and exposure dose were compared between the two groups. Besides, the effective rate, success rate of superselective arterial catheterization, lipiodol deposition rate and the incidence rate of complications of the two groups were observed and recorded. RESULTS: Compared with those in control group, the dose of contrast agent and exposure dose were lower in observation group, and the operation time in the former was significantly shorter than that in the latter. The effective rate was 74.19% in observation group and 48.39% in control group. Moreover, in comparison with control group, operation group exhibited a higher effective rate, a higher success rate of superselective arterial catheterization and a higher lipiodol deposition rate, showing statistically significant differences (p<0.05). Besides, the incidence rate of complications (including myelosuppression, gastrointestinal discomfort and infection, 4.88%) in observation group was markedly lower than that in control group (25.81%) (p<0.05). CONCLUSION: 3D-DSA under contrast guidance during interventional treatment of patients with HCC can significantly improve the therapeutic effect, and it is of great importance to reduce the incidence rate of complications and enhance the safety of interventional treatment.
Human β-defensin 1 Functions as a Tumor Suppressor via ER Stress-triggered JNK pathway in Hepatocellular Carcinoma.
Li X, Song W, Zhang M … +1 more , Zhao P
J BUON · 2021 · PMID 34564993
PURPOSE: Human β-defensin 1 (DEFB1) belongs to defensins family that contribute to innate immune responses and was recently found to downregulate a variety of cancers, including renal, prostatic, and oral squamous cell c...
PURPOSE: Human β-defensin 1 (DEFB1) belongs to defensins family that contribute to innate immune responses and was recently found to downregulate a variety of cancers, including renal, prostatic, and oral squamous cell carcinoma, and therefore is considered as a potential tumor suppressor. However, the role of DEFB1 in hepatocellular carcinoma (HCC) still needs to be elucidated. METHODS: Quantitative PCR and Western blot were used to measure the expression levels of interested proteins. CCK-8 and colony formation assays were performed to determine the ability of cell proliferation. Tumor formation experiments in nude mice were used to examine the tumor growth. RESULTS: The expression level of DEFB1 was dramatically downregulated in human HCC. Quantitative PCR and Western blot results also showed a pronounced decrease of DEFB1 expression in the liver cancer cell lines. Rescuing the expression of DEFB1 in Huh7 cells effectively suppressed cell proliferation and reduced the colony forming ability, probably by inducing cell apoptosis and cell cycle arrest. Moreover, tumor formation experiments in nude mice also showed inhibition of tumor growth by DEFB1 expression in vivo. Furthermore, induction of DEFB1 expression induced degraded protein increase and endoplasmic reticulum (ER) stress, which subsequently activated JNK pathway. Pharmacologic inhibition of ER stress by 4-phenylbutyrate, a compound to alleviate ER stress, effectively eliminated DEFB1-induction inhibition of cell proliferation and migration. CONCLUSION: DEFB1 functions as a tumor suppressor in HCC through activating ER stress and JNK pathway, which may provide a potential strategy for HCC treatment.
Efficacy and safety of sorafenib combined with TACE in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Li D, Pang Y, Xu L … +1 more , Xu X
J BUON · 2021 · PMID 34564992
PURPOSE: Sorafenib combined with transcatheter arterial chemoembolization (TACE) is one of the common methods in the clinical treatment of advanced hepatocellular carcinoma (HCC), but its efficacy and safety are still co...
PURPOSE: Sorafenib combined with transcatheter arterial chemoembolization (TACE) is one of the common methods in the clinical treatment of advanced hepatocellular carcinoma (HCC), but its efficacy and safety are still controversial. Therefore, we used meta-analysis to evaluate the efficacy and safety of sorafenib combined with TACE in the treatment of advanced HCC. METHODS: Up to March 14, 2021, the databases of PubMed, EMBASE, Cochrane Library, CNKI and Wanfang were searched, and the randomized controlled clinical trials (RCTs) of sorafenib combined with TACE in the treatment of primary HCC were included. Two researchers independently screened the literature, extracted data and evaluated the quality according to the inclusion and exclusion criteria. Revman5.4 software was used for meta-analysis. RESULTS: A total of 3076 patients were included in 23 studies, including sorafenib combined with TACE group (n=1542) and TACE group (n=1534). The results of meta-analysis showed that sorafenib combined with TACE could increase the objective response rate (ORR) (RR=1.35, 95%CI: 1.24-1.48, p<0.00001), disease control rate (DCR) (RR=1.19, 95%CI: 1.11-1.28, p<0.00001), prolong the time of disease progression (TTP) (HR=0.80, 95%CI: 0.70-0.92, p=0.001), reduce the expression level of alpha-fetoprotein (AFP) (SMD=2.01, 95%CI: 1.27-2.75, p<0.00001) and vascular endothelial growth factor (VEGF) (SMD=2.62, 95% CI: 1.35-3.90, p<0.0001) in serum. However, the overall survival (OS) was not prolonged (HR=0.86, 95%CI: 0.73-1.02, p=0.09). The incidences of fatigue, diarrhea, elevated bilirubin, skin reaction of hands and feet, rash, hypertension and oral mucosal inflammation in sorafenib combined with TACE group were higher than those in TACE group (p<0.05). CONCLUSION: Sorafenib combined with TACE has some clinical benefits compared with TACE alone, but it does not seem to prolong the OS of patients with HCC, and the incidence of adverse reactions is higher, so more high-quality RCTs are needed to further study the efficacy of the combination regimen.
Predictive value of and relationship between the gamma-glutamyl transpeptidase to lymphocyte ratio and CT features in hepatocellular carcinoma patients with postoperative adjuvant TACE.
Zhao H, Liu X, Xu R … +2 more , Guo X, Shen A
J BUON · 2021 · PMID 34564991
PURPOSE: To explore the predictive value of and the relationship between the gamma-glutamyl transpeptidase (GGT) to lymphocyte ratio (GLR) and computed tomography (CT) features in hepatocellular carcinoma (HCC) patients...
PURPOSE: To explore the predictive value of and the relationship between the gamma-glutamyl transpeptidase (GGT) to lymphocyte ratio (GLR) and computed tomography (CT) features in hepatocellular carcinoma (HCC) patients with postoperative adjuvant transarterial chemoembolization (PA-TACE). METHODS: Between January 2012 and June 2015, 150 HCC patients who underwent adjuvant TACE after hepatectomy in the Affiliated Hospital of Nantong University were selected. Baseline parameters, laboratory values, clinical variables, and CT features (including CT values, irregular rim-like arterial phase enhancement (IRE), and CT enhanced values) were evaluated in all of the patients. The Mann-Whitney U test was performed to assess the GLR values between the patients with microvascular invasion (MVI) and those without MVI. Spearman correlation analysis was performed to evaluate the relationship between IRE and GLR. A nomogram based on the multivariate analysis was constructed. RESULTS: Using multivariate analysis, GLR, MVI, α-fetoprotein levels, and IRE were found to be independent prognostic factors for overall survival (OS). In the MVI group, the GLR of patients was higher than that in the non-MVI group (z=-6.652, p<0.001). We observed a clear correlation between GLR and IRE (r=0.522, p<0.001). The nomogram was constructed and the calibration curve showed excellent predictive performance. CONCLUSIONS: We observed a correlation between GLR and CT features in HCC patients. The nomogram based on clinical data, pathological data, and CT features was suggested to predict the 5-year survival of HCC patients with PA-TACE, which offers an accurate, comprehensive, and reliable evaluation for individualized treatment.
Expression of miR-187 and miR-509-3p in serum of primary hepatocellular carcinoma patients and its evaluation of prognosis.
Dai G, Shen S, Liu Y … +4 more , Ma X, Fang Y, Weng Y, Li C
J BUON · 2021 · PMID 34564990
PURPOSE: Hepatocellular carcinoma (HCC) is a histological type of primary liver cancer, with high recurrence and mortality rates worldwide. At the moment, there are no diagnostic and prognostic markers. microRNAs (miRs)...
PURPOSE: Hepatocellular carcinoma (HCC) is a histological type of primary liver cancer, with high recurrence and mortality rates worldwide. At the moment, there are no diagnostic and prognostic markers. microRNAs (miRs) are short-chain non-coding RNAs, and play a vital role in tumor diagnosis and prognosis. METHODS: The miR-187 and miR-509-3p expression in primary HCC was evaluated via qRT-PCR and starBase, and the diagnostic and prognostic values were analyzed via receiver operating characteristic (ROC) curve and Kaplan-Meier method. RESULTS: qRT-PCR and starBase analysis showed that the miR-187 expression was low in the tissues and serum of primary HCC patients, while that of miR-509-3p increased. ROC analysis manifested that the area under the curves (AUCs) of miR-187 and miR-509-3p in primary HCC were 0.842 and 0.866, respectively, and that of joint diagnosis was > 0.9. The 5-year survival rates of miR-187 low expression group and miR-509-3p high expression group decreased markedly. Cox regression analysis identified that pathological differentiation, clinical stage and miR-187 were independent prognostic factors of primary HCC patients. CONCLUSION: miR-187 and miR-509-3p.
FBXL19-AS1 aggravates the progression of hepatocellular cancer by downregulating KLF2.
Chen Y, Yang L
J BUON · 2021 · PMID 34564989
PURPOSE: To uncover the role of FBXL19-AS1 in aggravating the progression of hepatocellular cancer (HCC) by downregulating kruppel-likefactor2 (KLF2). METHODS: FBXL19-AS1 level in HCC tissues and adjacent normal tissues...
PURPOSE: To uncover the role of FBXL19-AS1 in aggravating the progression of hepatocellular cancer (HCC) by downregulating kruppel-likefactor2 (KLF2). METHODS: FBXL19-AS1 level in HCC tissues and adjacent normal tissues were firstly determined. Its level in HCC with different tumor sizes (≤ 5 cm or > 5 cm) and different tumor stages (stage I-II or III-IV) was examined as well. Subcellular distribution of FBXL19-AS1 was detected. The regulatory effect of FBXL19-AS1 on viability, apoptosis and cell cycle progression of HCC cells was assessed. RNA immunoprecipitation (RIP) assay was conducted to explore the interaction between FBXL19-AS1 with EZH2 and SUZ12. Moreover, chromatin immunoprecipitation (ChIP) assay was carried out to identify the recruitment ability of FBXL19-AS1 on EZH2 and H3K27me3. Finally, the potential role of KLF2 in FBXL19-AS1-mediated HCC proliferation was investigated. RESULTS: FBXL19-AS1 was highly expressed in HCC tissues, especially in those larger than 5 cm in tumor size and worse tumor stage. FBXL19-AS1 was mainly distributed in nucleus and interacted with EZH2 and SUZ12. Knockdown of FBXL19-AS1 suppressed proliferation, cell cycle progression and induced apoptosis of HCC cells. Moreover, silence of FBXL19-AS1 attenuated the recruitment ability of EZH2 on KLF2. Knockdown of KLF2 reversed the regulatory effect of FBXL19-AS1 on proliferative ability of HCC cells. CONCLUSIONS: Long non-coding RNA (lncRNA) FBXL19-AS1 is upregulated in HCC. It accelerates proliferative ability, cell cycle progression and suppresses apoptosis of tumor cells through interacting with KLF2, thus aggravating the progression of HCC.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe